광동제약
009290KOSPI55.4 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
Guangdong Pharmaceutical operates through three divisions—OTC, ETC, and F&B—selling products like Cheongshimwon, Jeju Samdaewon, and Gardasil, with 98.6% of sales coming from the domestic market. In 2025, the company achieved sales of 10.11 trillion KRW and aims to expand into natural product markets, digital innovation, and healthcare platforms to become a 'Human Healthcare Brand' enterprise.
Number of Employees
1,022people
Average Salary
78.4M KRW
Score Calculation Basis
Detailed Financial Score
In line with industry avg
Half of industry avg (excellent)
Well below industry avg
Half of industry avg (excellent)
Avg ▲4.7% (2-year basis)
Avg ▼12.7% (2-year basis)
Avg ROE 5.7% (declining, 3yr)
Detailed News Sentiment
- Positive핑거, 토큰증권 제도화 수혜 주목…CMIR “F-STO 사업 확대”
핑거의 토큰증권 플랫폼 F-STO가 제도화로 인해 사업 확장 기회가 확대될 것으로 예상되어 긍정적 영향이 기대됩니다.
- Neutral제약·바이오 상위 10곳, 상반기 법인세 6144억…삼바·셀트리온이 8...
전반적인 제약바이오 산업의 법인세 증가 추세는 광동제약에 직접적인 영향을 미치지 않음.
- Positive광동제약, 대한피클볼협회와 스폰서십…‘비타500 이온킥’ 스포츠 마.....
광동제약의 피클볼 스폰서십 협약으로 스포츠 마케팅 활동 강화 및 브랜드 인지도 상승 기대.
Detailed Momentum
Near 52w low (17%, downtrend)
1m -2.79% (slight drop)
Volume decreasing
Detailed Disclosure
- Neutral최대주주등소유주식변동신고서2026-08-28
- Neutral반기보고서 (2026.06)2026-08-14
- Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-08-12
